(Q43237425)

17 November 2017

title

A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction (English)

1 reference

17 November 2017

main subject

myocardial infarction

1 reference

1 reference

M Marinsek

1

1 reference

17 November 2017

Andreja Sinkovic

series ordinal

2

1 reference

17 November 2017

language of work or name

1 reference

1 September 2009

1 reference

Journal of International Medical Research

17 November 2017

published in

1 reference

17 November 2017

volume

37

1 reference

17 November 2017

issue

5

1 reference

17 November 2017

page(s)

1577-1587

1 reference

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Angiotensin receptor blockers and risk of myocardial infarction: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

PAI-1 and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Pivotal role of plasminogen-activator inhibitor 1 in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Plasminogen activator inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Simvastatin combined with ramipril treatment in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

Atrial natriuretic peptide and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700536

10.1177/147323000903700536

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference